An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed within households. The results could be particularly important for families where someone is at high risk of serious complications from the illness. The drug, ensitrelvir, is already approved in Japan to treat mild to moderate COVID cases. The SCORPIO-PEP trial, however, has demonstrated that it also has the potential to protect against illness. Uninfected people who began taking the antiviral within 72 hours of symptoms first appearing in a household member were significantly less likely to contract COVID-19 than people who were given...